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Synopsis
Insulin-like growth factor-I (IGF-I) is closely related to insulin but has distinct metabolic actions.
IGF-I is an important stimulant of protein synthesis in muscle but it also stimulates free fatty acid
utilization. Important indirect effects of IGF-I that influence metabolism include suppression of
growth hormone secretion and at supraphysiologic concentrations suppression of insulin secretion.
IGF-I actions are regulated by IGF binding proteins and in obesity and metabolic syndrome there
is major dysregulation of IGF binding protein secretion resulting in alterations in the concentration
of free IGF-I and IGF-I actions. In type 1 diabetes, IGF-I synthesis is markedly impaired and in
type 2 diabetes multiple changes occur in IGF-I actions including sensitization to its mitogenic
actions in some target tissues. Administration of IGF-I to patients with extreme insulin resistance
results in improvement in glycemic control and IGF-I has been shown to be associated with
lowering glucose and enhancing insulin sensitivity in both type 1 and type 2 diabetes. However
diabetics are also quite sensitive to stimulation of side effects in response to IGF-I and this has
greatly limited its usefulness as a hypoglycemic agent. IGF-I coordinately links growth hormone
and insulin actions as well as having direct effects on intermediary metabolism.
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Introduction
Insulin-like growth factor-I (IGF-I) has significant structural homology with insulin. The
structural conservation is due to the fact that proinsulin, IGF-I and IGF-II evolved from a
single precursor molecule approximately 60 million years ago. The function of that single
precursor molecule was to provide a chemical signal for cells within primitive organisms to
establish that adequate nutrient was present not only for basal metabolic needs but also for
protein synthesis and cell proliferation. At the time vertebrates appeared this system evolved
into one with more complexity in order to be able to store calories as fat. At that time insulin
diverged from IGF-I and the pituitary gland appeared along with growth hormone. The
function of these three hormones were linked to be able to regulate both nutrient availability
during periods of starvation and repletion as well as continuing to provide adequate signals
and substrate for growth. As such the regulation of synthesis and secretion of these three
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hormones is directly linked to nutrient intake. Since insulin, IGF-I and IGF-II evolved from
a single precursor they continue to share significant structural homology however there are
also distinct differences. The primary domains within IGF-I and insulin that determine
receptor binding have significant amino acid differences that account for major differences
in affinity for their respective receptors (1). Similarly the IGFs have the unique
characteristic of being able to bind to IGF binding proteins which is determined by a specific
amino acid sequence and in positions, 3, 4, 15, 16 of N terminus of IGF-I molecule and
homologous substitutions in IGF-II (2). These structural differences provide important
distinction for the regulation of IGF-I and insulin bioavailability and thus indirectly regulate
their effects on metabolism.
IGF-I and insulin have distinct receptors. Both receptors are tyrosine kinase containing
receptors and they show 48% amino acid sequence homology (3). In spite of these
similarities the ligand binding specificity is strict. The affinity of the IGF receptor is 1000
fold greater for IGF-I than insulin and the insulin receptor has a 100 fold greater affinity for
insulin compared to IGF-I. Insulin and IGF-I receptor densities vary widely among cell
types i.e. mature differentiated hepatocytes and adipocytes have abundant insulin receptors
whereas they have almost no IGF-I receptors. Conversely cell types such as vascular smooth
muscle cells have abundant IGF-I receptors and minimal insulin receptors. This difference in
receptor distribution accounts for many of the differences in insulin and IGF-I actions.
Growth hormone has an entirely different structure and its receptor belongs to the cytokine
receptor family (4). Growth hormone has a major regulatory influence on the metabolic
actions of both IGF-I and insulin and functions in several important ways that are quite
distinct from insulin and IGF-I to modulate nutrient availability that is necessary for both
balanced tissue growth and maintenance of normal intermediary metabolism. Therefore
coordinate regulation of the metabolic actions of these three hormones provides an
important basis for understanding their individual effects on intermediary metabolism and
how they function coordinately to maintain nutrient balance.
Nutrient regulation of IGF-I secretion
As can be predicted from the phylogenetic development of IGF-I the primary variable
regulating plasma IGF-I concentrations is nutrient intake. Both total caloric and protein
intake are important regulatory variables (5). The effect of caloric intake is such that if
caloric intake is reduced by approximately 50% there a significant reduction in IGF-I
secretion. The effects of protein are more graded in that even small reductions result in
changes in IGF-I (6). For each 25% reduction in protein intake there is an equivalent
reduction in IGF-I. The majority of the IGF-I in plasma (estimated at 80% based on mouse
genetic manipulation studies) is derived from hepatic synthesis (7). Both protein and energy
participate in the regulation of hepatic synthesis with energy regulating IGF-I gene
transcription and protein functioning primarily to regulate mRNA stability and translation. A
concomitant effect of changes in carbohydrate intake is the indirect effect that occurs as a
result of changes in insulin secretion. If carbohydrate is provided at a level of less than the
equivalent 700 kcal/day then even supplemental fat intake will not restore a normal IGF-I.
This is because IGF-I synthesis in the liver is also regulated by insulin (8). This is best
demonstrated by measuring serum IGF-I concentrations in untreated type I diabetics. When
they receive insulin they have a substantial increase in serum IGF-I (9). Studies in
experimental animals have also shown that blocking insulin action in the liver lowers serum
IGF-I. Therefore carbohydrate intake functions not only to increase the total amount of
energy that is available thereby increasing IGF-I synthesis but also by a direct effect of
insulin on IGF-I gene transcription in particular the ability of growth hormone to stimulate
IGF-I gene transcription (8).
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Growth hormone (GH) is the second variable that regulates IGF-I synthesis and secretion
but for the liver to respond to growth hormone with normal IGF-I synthesis requires
adequate nutrition. GH is a potent stimulant of IGF-I synthesis and GH administration to GH
deficient animals results in a brisk increase in IGF-I gene transcription in the liver that leads
to a major increase in serum IGF-I (10). The increase in serum IGF-I then feeds back on the
pituitary gland to suppress GH secretion and maintain homeostasis. IGF binding proteins are
another variable which regulates serum IGF-I concentrations. There are six IGF binding
proteins (11). IGFBP-3 is the principal binding protein in serum and its concentration is also
increased in response to GH and this change accounts for a significant fraction of the
increase in total IGF-I that occurs in response to GH. The increase in IGFBP-3 in response
to GH is also modulated by changes in nutrition. When IGF-I is bound to IGFBP-3 the
binary complex binds to a third protein termed acid labile subunit or ALS. ALS
concentrations are also GH dependent (12). This ternary complex prolongs the half life of
IGF-I in serum from less than 5 min to 16 hrs. IGFBP-5 is much less abundant then
IGFBP-3 but it also binds to ALS and its concentration increases in response to GH. Thus
changes in IGFBP-3, IGFBP-5 and ALS all function to increase the serum IGF-I
concentration by prolonging its half life. Two other IGF binding proteins, IGFBP-1, and -2
do not bind to ALS and therefore only prolong the half life of IGF-I to periods ranging
between 90 min and 2 hr. Therefore they have minimal effects in increasing total serum
IGF-I concentrations. However the regulation of serum concentrations of these proteins is
important for regulating IGF-I actions. Under normal circumstances IGFBP-3 and 5 are
saturated. Therefore abrupt changes in IGFBP-1 and -2 which are not saturated and which
occur as a result of changes in either nutrient intake or insulin secretion, can result in major
changes in free IGF-I and thereby regulate tissue responsiveness (13). Other hormones that
regulate IGF-I bioactivity include cortisol which antagonizes the actions of IGF-I and
therefore can result in an increase in serum concentrations, and thyroxine which is necessary
for normal IGF-I biosynthesis and which can stimulate an increase in IGF-I concentrations
in hyperthyroidism. Estrogens function to antagonize the ability of growth hormone to
stimulate IGF-I synthesis in the liver and testosterone alters IGF binding protein
concentrations. Additionally the growth hormone analog, human placental growth hormone
is an important stimulant of IGF-I synthesis in pregnancy. All of these hormones function
coordinately with changes in nutrient intake to modulate the ability of IGF-I to regulate both
growth and metabolism.
Metabolic effects of IGF-I
Although IGF-I is classically considered an important growth factor since it stimulates the
growth of all cell types it has major metabolic effects. This overarching effect of IGF-I on
metabolism is to provide a signal to cells that adequate nutrient is available to avoid
apoptosis, enhance cellular protein synthesis, enable cells to undergo hypertrophy in
response to an appropriate stimulus and to allow stimulation of cell division. Therefore even
in cytostatic adult tissues such as neurons and fused skeletal myoblasts, IGF-I can provide
important trophic effects that lead to changes in cellular metabolism. Since IGF-I receptors
are ubiquitous, these responses can occur in all cell types. Therefore the signal induced by
IGF-I stimulation of its receptor provides a mechanism for coordinating protein,
carbohydrate or fat metabolism among various cell types. Importantly each of these
processes is regulated coordinately with insulin and in the appropriate target tissue, either
insulin or IGF-I may be the primary determinant of each of these processes. Similarly
growth hormone functions to coordinately regulate the ability of each of these hormones to
modulate all three processes.
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In cells in tissue culture, IGF-I is a potent stimulant of protein synthesis. This response is
modulated by the PI-3 kinase pathway. Following IGF-I receptor activation the receptor
tyrosine kinase phosphorylates tyrosines on the adaptor protein termed insulin receptor
substrate-1 (IRS-1) (14). This provides a binding site for the p85 subunit of PI-3 kinase
which is then activated. Activation of PI-3 kinase results in coordinate stimulation of AKT
which then leads to suppression of TSC-2 and activation of mTORC1 complex. This
functions to stimulate phosphorylation of p70S6 kinase and E4B1, a translational repressor.
These coordinate actions allow major increases in cellular protein synthesis. The process is
modulated by the nutrient sensitive AMP kinase which is activated by nutrient restriction
and phosphorylates serine 794 on IRS-1 which inhibits its ability to be activated thus leading
to PI-3 kinase inhibition and inhibition of IGF-I stimulated protein synthesis (15). In skeletal
muscle IGF-I stimulates amino acid transport but it also is a direct stimulant of protein
synthesis and an important inhibitor of protein breakdown (16). The atrogin complex whose
assembly can be triggered by a variety of catabolic stimuli including glucocorticoid excess is
antagonized in the presence of IGF-I stimulation. Conversely mice that have been
genetically altered to constitutively activate this complex are resistant to the anticatabolic
effects of IGF-I (17). This catabolic response is mediated through MURF1 and atrophy
MAF box which is also termed atrogin. These are E3 ubiquitin ligases and their expression
increases during disuse atrophy, following glucocorticoid administration or in response to
cytokine stimulation. MAF box upregulation can be antagonized by IGF-I treatment leading
to inhibition of proteosome formation thus reducing the targeting of proteins for degradation
and reducing the rate of catabolism (18). Insulin can have similar physiologic actions. These
effects are mediated in part by the ability of AKT to phosphorylate serine 32 on FOXO3A
which results in exclusion of FOXO3A from the nucleus. mTOR also blocks MURF1 and
MAF box transcription. Studies by Kelly and coworkers have shown that cytokines which
are activated in catabolic states and initiate muscle breakdown through MURF1 and MAF
box induction can be antagonized in part by IGF-I actions (19). Thus exogenous expression
of IGF-I in skeletal muscle of animals can partially reverse the effect of cytokine or
glucocorticoid stimulation on catabolism even in insulin resistant states.
IGF-I functions both under normal conditions and under conditions of either protein
deprivation or when an excess of cytokine stimulation is present to attenuate catabolism.
When IGF-I is administered to healthy volunteers it stimulates protein synthesis but if
catabolism has not been stimulated it has minimal effects on proteolysis (20). However at
high concentrations it can suppress proteolysis even within normally fed subjects. GH
administration also results in an increase in protein synthesis but the extent to which GH
stimulates this response completely independently of IGF-I has not been determined. Of
note administration of a relatively high concentration of IGF-I (10 mcg/kg/hr) to patients
with growth hormone receptor mutations resulted in a significant stimulation of protein
synthesis (21). However coadministration of growth hormone and IGF-I to normally fed
normal subjects does not result in a greater response when compared to the individual
response to each hormone given separately. However following caloric deprivation
administration of growth hormone and IGF-I results in a synergistic increase in protein
balance. In growth hormone deficient adults both GH and IGF-I are anabolic and enhance
protein synthesis (22). Insulin can inhibit proteolysis in muscle at very low concentrations
but the concentrations that are required to stimulate protein synthesis are higher. Thus it
would be reasonable to conclude that IGF-I is the major factor maintaining protein synthesis
during relatively long intervals between meals but insulin is a primary factor stimulating
anabolism in skeletal muscle following ingestion of a meal that contains a normal protein
content.
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Both growth hormone and IGF-I have been used experimentally in catabolic illnesses and
have been shown to improve nitrogen retention and protein synthesis when administered to
patients with severe catabolic conditions such as, burns and renal failure (23, 24). Similarly
patients being treated with high doses of corticosteroids respond to IGF-I with induction of
an anabolic response (20). IGF-I can also reduce the effect of loss of gonadal function on
protein balance. Young men who were administered a gonadotrophin receptor antagonist
who became catabolic responded to either GH or IGF-I with a significant increase in protein
synthesis although it appeared GH was more potent than IGF-I since it induced an increase
in androgen receptor number in skeletal muscle (25).
Fat metabolism
Although mature adipocytes do not express IGF-I receptors, preadipocytes have abundant
IGF-I receptors and IGF-I stimulates preadipocyte differentiation (26). However as
preadipocytes differentiate, they markedly reduce their IGF-I receptor number and insulin
receptors become predominant. Thus in well formed adipose tissue beds, physiologic
concentrations of IGF-I are not effective in stimulating changes in lipid synthesis or lipolysis
and IGF-I has effects on primary adipocytes only at very high concentrations which are
capable of stimulating glucose transport through the insulin receptor. In contrast both GH
and insulin are potent modulators of these processes. GH has direct effects on mature
adipocytes that result in the release of free fatty acids following triglyceride breakdown and
in increased free fatty acid oxidation in liver (27). GH also enhances the lipolytic effect of
catecholamines by increasing adrenergic receptor number in adipocytes. In skeletal muscle,
GH increases lipoprotein lipase activity thus facilitating free fatty acid utilization. Insulin is
a potent stimulant of lipid synthesis and insulin antagonizes triglyceride breakdown. This
occurs both in skeletal muscle and liver as well as fat. An increase in free fatty acid flux
from adipose tissue to liver can result in insulin resistance in the liver and growth hormone
is known to antagonize insulin action through this mechanism (28). IGF-I is a potent
stimulant of free fatty acid uptake and oxidation in skeletal muscle. In an interesting mouse
model Yakar et al knocked out the IGF-I receptor in skeletal muscle. This also knocked out
the insulin/IGF-I hybrid receptor and to some extent reduced the biosynthesis of insulin
receptor homodimers. This resulted in the development of type II diabetes over time (29).
That this was related to loss of the ability of IGF-I stimulate free fatty acid transport in
muscle was strengthened by their observation that the phenotype could be rescued by
expressing CD36, a known fatty acid transporter in muscle (30). This led to the conclusion
that it is the effect of IGF-I on fatty acid transport in muscle that is mediating this response
and that it is so profound that its inhibition can lead to extreme insulin resistance and
diabetes. Therefore an important metabolic effect of IGF-I is to reduce flux of free fatty
acids through the liver which results in an enhancement of the ability of insulin to suppress
hepatic glucose output. Supraphysiologic concentrations of IGF-I also suppresses insulin
secretion and this may result in inhibition of insulin's lipogenic effect in fat. Therefore the
two major effects of IGF-I that may be enhanced free fatty acid utilization by muscle which
results in increased free fatty acid flux in the liver and loss of insulin's lipogenic effect in fat.
Suppression of GH by IGF-I also results in decreased free fatty flux in the liver and
decreases the amount of substrate available for enhancement of lipid oxidation directly in
skeletal muscle thus reducing the total free fatty acid flux. This mechanism probably
functions under normal conditions to regulate glucose homeostasis and GH induced insulin
resistance. Chronic administration of IGF-I to human subjects has been shown to decrease
fat mass rates in GH deficient adults probably secondary to insulin suppression of insulin
induced lipogenesis. Chronic administration of IGF-I to patients who had GH receptor
defects showed increased lipolysis and lipid oxidation rates and loss of total fat mass (21).
The degree of change was similar to the effect of GH when it was administered to GH
deficient subjects.
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Effects on carbohydrate metabolism
An understanding of the effect of IGF-I on carbohydrate metabolism is dependent upon
knowledge of its effects in modulating insulin and GH actions. IGF-I reduces serum GH
concentrations and it also reduces GH's direct effects on insulin suppression of hepatic
gluconeogenesis and by increasing free fatty acid uptake in muscle it indirectly enhances
hepatic insulin action (31). In both fat and liver GH stimulates the synthesis of the p85
subunit of PI-3 kinase (32). This relative increase in p85 leads to suppression of p110
subunit activity thus leading to antagonism of insulin action (33). Therefore IGF-I may
indirectly modulate carbohydrate metabolism through both GH suppression and
enhancement of insulin action. Following ingestion of a meal there is a significant increase
in free IGF-I. This occurs via insulin induced suppression of IGFBP-1 secretion (34). The
IGFBP-1 gene is transcriptionally regulated by insulin thus the meal induced increase in
insulin leads to an increase in free IGF-I. This change may be adequate to stimulate fatty
acid oxidation in muscle and suppress GH and these changes may to occur at physiologic
IGF-I levels. Provision of pharmacologic levels of IGF-I to normal subjects results in further
changes in carbohydrate metabolism. IGF-I can directly stimulate glucose transport into
muscle through either IGF-I or insulin/IGF-I hybrid receptors (35, 36) although this requires
relatively high concentrations of free IGF-I. Additionally a high concentration of free IGF-I
can directly suppress renal gluconeogenesis in mice (37). Experimental mice in whom the
insulin receptor has been deleted show a decrease in blood glucose in response to IGF-I
indicating that in part its effect can be mediated directly through stimulation of glucose
transport by the IGF-I or the hybrid receptor (38). Experimental mice in which serum IGF-I
is lowered by 80% by deleting expression in the liver have impaired glucose tolerance (39).
However whether this is a direct effect of reduced IGF-I or due to an increase in GH, it has
been difficult to determine because GH levels increase substantially in these mice. Therefore
the extent to which the effect of IGF-I on lowering glucose is due to the direct of effect of
IGF-I on glucose transport, enhancement of FFA metabolism in muscle or suppression of
GH has been difficult to ascertain. In a comparable study we infused a GH receptor
antagonist into patients with acromegaly and showed that it improved their insulin
sensitivity (40). We then repeated the experiment and added an IGF-I infusion. Although
IGF-I was infused at supraphysiologic concentrations, these concentrations were capable of
further improving insulin sensitivity and lowering glucose even when the activity of GH had
been completely suppressed. Simpson et al showed that following suppression of GH with
octreotide in Type I diabetic patients IGF-I could further lower glucose (41). This suggests
at least at pharmacologic levels, IGF-I does function to enhance insulin sensitivity and lower
glucose independently of its ability to suppress GH. However in GH deficient individuals
administration of a physiologic replacement concentration of IGF-I does not change
carbohydrate oxidation but in patients with GH receptor mutations it resulted in enhanced
carbohydrate oxidation. It also increased hepatic glucose production rates which was
probably due to suppression of insulin but, overall normoglycemia was maintained (32).
This also supports the conclusion that IGF-I has a glucose lowering effect secondary to its
ability to increase fatty acid oxidation in muscle leading to decreased free fatty acid flux to
the liver and enhanced insulin suppression of hepatic glucose output. Thus the predominant
effect of IGF-I on carbohydrate metabolism appears to be secondary to its effects on lipid
metabolism. Because suppression of insulin and GH secretion occurs at pharmacologic
levels of IGF-I it is difficult to extrapolate from the results of most published studies and
conclude that these effects occur at normal physiologic levels. However GH suppression
would be expected to lead to decreased free fatty acid flux in liver and reduced antagonism
of insulin action on glucocogenesis.
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IGF system component concentrations and their utility in predicting
changes in carbohydrate and fat metabolism
Serum IGF-I concentrations vary widely among normal human subjects. Age is a major
determinant and serum levels are low at birth and rise progressively with a peak during
puberty then decrease progressively with the greatest decrease occurring during the second
and third decades, but levels continue to decrease throughout the lifespan (42). These
changes parallel the age- dependent changes in GH secretion. Changes in the GH dependent
IGF binding proteins, IGFBP-3 and -5, as well as the acid labile subunit parallel the changes
that occur in serum IGF-I; although changes in IGFBP-3 are significantly less sensitive to
changes in GH because IGF-II which is relatively insensitive to changes in GH is a major
determinant of serum IGFBP-3 and to some extent ALS (43). Other IGF binding proteins
that are non-growth hormone dependent such as IGFBP-1 and 2 have been studied
extensively in humans. Insulin is a major suppressor of hepatic IGFBP-1 synthesis therefore
changes in IGFBP-1 often reflect changes in either insulin secretion or insulin sensitivity
(44). IGFBP-2 changes much less rapidly in response to insulin however chronic changes in
insulin availability or insulin sensitivity can lead to changes in IGFBP-2 (45). As noted
previously changes in these two proteins can have major effects on the plasma concentration
of free IGF-I. Acute changes in several nutritional variables regulate IGF-I secretion and
plasma concentrations however chronic changes in dietary intake that lead to changes in fat
mass also regulate IGF-I and GH. In general when body mass index rises above 24 there is a
substantial increase in serum IGF-I concentrations (46). Studies have shown that this change
occurs as a function of enhanced sensitivity to the ability of GH to stimulate IGF-I synthesis
(47). This change plateaus with a body mass index of 25 and remains relatively constant
until body mass index reaches 36. At that point although the enhanced sensitivity to GH is
maintained there is a reduction in GH secretion. Therefore massively obese patients have
lower 24 hr blood production rates of GH. This effect becomes predominant with BMI >37
and serum IGF-I concentrations tend to decrease as a function of increasing weight in this
subgroup (48). There are also changes in binding proteins that occur as a result of obesity
and the net effect is a moderate increase in free IGF-I when body mass index increases
above 30 (49). This change in free IGF-I correlates with a lowering of IGFBP-1 which
presumably occurs as a result of hyperinsulinemia.
IGF-I and the metabolic syndrome
Several studies have attempted to correlate total plasma IGF-I concentrations with the
presence of the metabolic syndrome. In general patients with a low normal IGF-I who are
obese and meet other criteria for metabolic syndrome tend to have a worse cardiovascular
disease outcome than those with a mid to high normal IGF-I (50). Clearly many of these
subjects have insulin resistance. Whether the degree of resistance or the accompanying
changes in inflammatory cytokine secretion is the predominant predictor of a poor outcome
has not been definitively determined. There are also studies correlating the lower total serum
IGF-I concentrations with increased waist to hip ratios or with the development of impaired
glucose tolerance both of which predict a worse cardiovascular outcome (51, 52). Therefore
although it appears that a lower serum IGF-I predicts a worse cardiovascular outcome the
exact parameter that is mediating this increased risk has not been determined. Cytokines that
are elevated in these patients such as C reactive protein are known to decrease circulating
IGF-I in experimental animals (53) and could contribute to the relationship between low
serum IGF-I and the prediction of a poor cardiovascular outcomes.
In patients with type 1 diabetes, the changes in serum IGF-I are relatively straightforward. In
poorly controlled type 1 diabetes, the lack of adequate insulinization of the liver leads to a
major suppression of IGF-I biosynthesis (54). Thus acute administration of insulin to type 1
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diabetics results in a 3–3.5 fold increase in serum IGF-I due to restoration of a hepatic
synthesis (9). Administration of insulin via the portal circulation results in a greater increase
in serum IGF-I in type 1 diabetes compared to peripheral insulin administration (55). Thus
in poorly controlled adolescent type 1 diabetics IGF-I can be low enough that optimal
growth is not achieved. That this is rate limiting for growth was shown in experimental
animals with diabetes and low IGF-I levels in whom a growth response was achieved when
the IGF-I levels were normalized (56). Even though GH concentrations are elevated in these
animals they are relatively refractory to the high GH concentrations due to a low serum IGF-
I that is inadequate to sustain normal growth. In addition in poorly controlled diabetes there
is increased catabolism particularly in skeletal muscle (57). In type 2 diabetes the range of
IGF-I concentrations that has been reported is broad (58). This suggests that because of
multiple variables that are interacting to control IGF-I concentrations such as increases in
inflammatory cytokines, decreases in hepatic insulin action due to insulin resistance,
concomitant changes in IGF binding proteins and the effects of obesity upon IGF-I
production, that the net effect of all these variables combined is that there is not a uniform
abnormality in serum IGF-I concentrations in this disease state.
In contrast to total IGF-I levels, IGFBP levels are significantly altered in type 2 diabetes and
these changes result in changes in free IGF-I (59). Recent studies from Sweden in
prediabetics suggest that IGFBP-1 is initially lower in subjects who will subsequently
develop type 2 diabetes (60). This is due to hyperinsulinism which occurs in the early
prediabetic phase of disease. This results in an elevation in free IGF-I however as insulin
resistance progresses the liver becomes more resistant to insulin suppression of IGFBP-1
and IGFBP-1 levels rise which is concomitantly accompanied by a decrease in free IGF-I
(60). Therefore there may be a natural progression of changes in total IGF-I and free IGF-I
that occur as a function of changing insulin secretion and insulin sensitivity over time in
type 2 diabetes. That a change in free IGF-I that occurs as function of changes in IGFBP-1
could be clinically significant was shown by administration of IGFBP-1 to experimental
animals using concentrations that were sufficient to lower free IGF-I significantly and
showing that this resulted in increased serum glucose even in absence of a change in insulin
(61). Administration of insulin to type 1 diabetics not only results in a major increase in total
IGF-I levels but also free IGF-I levels are increased substantially and IGFBP-1 decreases
approximately 5 fold (9). IGFBP-2 is suppressed in obesity and this may contribute to the
increase in free IGF-I (62). The suppression of IGFBP-2 in obese subjects may be
physiologically relevant since transgenic mice that overexpressed IGFBP-2 are relatively
resistant to the development of obesity during high fat feeding suggesting that this protein
may have a direct effect on preadipocyte differentiation (63). A further confounding variable
is IGFBP-3 proteolysis which occurs in diabetes and results in disproportionate increases in
free IGF-I as a function of diabetic control (64, 65).
IGFBP changes also correlate with parameters of metabolic syndrome and lower IGFBP-1
levels are present in metabolic syndrome patients with higher CRP. The combination of a
high CRP with a low IGFBP-1 value is a strong predictor of the presence of this syndrome
(66, 67). Similarly in middle aged men with a low IGF-I and high CRP along with low
testosterone predicted the presence of metabolic syndrome with high probability (68). Low
IGFBP-2 also predicted the presence of metabolic syndrome and low IGFBP-2 was
associated with elevated fasting glucose (61). Whether these factors reflect insulin resistance
and the known effect of inflammatory mediators in suppressing IGF-I concentrations and
thereby suppressing IGFBP-1 and −2 or whether the primary changes in IGFBP-1 and −2
predispose to the development of obesity and insulin resistance has not been resolved.
Studies in transgenic mice overexpressing IGFBP-1 show that this induces hyperinsulinemia
and glucose intolerance and that the ability of IGFBP-1 to induce these changes is dependent
upon its phosphorylation state which is known to be increased in diabetes (69). Similarly
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following weight loss there is a significant increase in IGFBP-1 and IGFBP-2 both in
children and adults which correlates with an improvement in insulin sensitivity (70, 71).
These findings raise the question as to whether changes in IGF-I or IGFBP-1 and −2 can
predict the development of diabetes. Diet induced obesity in experimental animals induces
resistance to the vasodilitatory effects of IGF-I. Likewise Zucker rats which are extremely
obese are resistant to the glucose lowering effects of IGF-I (72). Since IGF-I modulates the
concentrations of IGFBP-1 and −2 it is possible that these values change as a function of
early changes in insulin resistance. A recent study utilized IGFBP-1 concentrations to
predict the development of type 2 diabetes in women in Sweden. Patients with the lowest
fasting IGFBP-1 measurements had high waist circumference and those in the lowest tertile
had the highest risk of developing diabetes within 8 years (60). These patients not only have
low fasting IGFBP-1 levels but impaired IGFBP-1 suppression after oral glucose loading.
Interestingly fasting IGFBP-1 values increased over the 8 year interval suggesting that the
subjects developed hepatic insulin resistance. Plasma IGF-I is associated with insulin
sensitivity in prediabetic subjects with different degrees of glucose intolerance. During a 4.5
year follow up of 615 subjects who had IGF-I values in the lower half of the normal range
had increased predisposition to develop glucose intolerance or type 2 diabetes and this
change was independently associated with IGFBP-1 (73). Maternal IGF-I/IGFBP-1 ratios
also predict the subsequent risk for gestational diabetes and IGFBP-1 values greater than 68
ng/ml lowered the risk by 57%. A free IGF-I greater than 1 ng/ml lowered the risk by 69%
(74). In older individuals (> than 65 years) low IGFBP-1 also predicts an increased risk for
glucose intolerance. Subjects with a low IGFBP-2 (10th percentile) had an increased hazard
ratio for the development of type 2 diabetes and those with IGFBP-1 above the 90th
percentile had a reduced risk. After adjustment for all metabolic parameters, the increased
relative risk ratio of a low IGFBP-1 remained present. IGFBP-1 also predicted the
development of type 2 diabetes over a 17 year period. Subjects in the lowest quintile had an
incidence of 12.6% whereas those in the highest quintile it was 1.5% (66). When corrected
for age, gender, CRP and waist circumference, those in the lowest quartile still had an
elevated relative risk ratio. Low insulin-like growth factor-II levels also predict weight gain
in normal weight middle aged subjects with type 2 diabetes. Those in the highest quartile
had a 47% decrease in risk of gaining more than 2 kg for a 5 year follow up period. IGF-I is
also negatively correlated with visceral fat mass suggesting that regional distribution in fat
may be predicted by IGF-I concentrations (76).
Genetic studies
IGF-I gene polymorphisms and changes in metabolism
A polymorphism due to a CA dinucleotide repeat in a microsatellite that is 1 kilobase
upstream from the IGF-I transcription start site results in lower serum IGF-I levels and some
investigators have found this is associated with a lower birth weight (77). This occurs in
approximately 11% of the Dutch caucasian population. A study of 477 Dutch patients with
evidence of ischemic heart disease and 808 control subjects demonstrated an increase
relative risk of 1.7:1 for the presence of ischemic disease in noncarriers of this common
polymorphism allelle (e.g. 192 based pairs). These subjects were also significantly shorter
and had an 18% reduction in serum IGF-I (78). Two other studies conducted in different
countries however were not able to reproduce this finding. There is a single nucleotide
polymorphism at position −202. A polymorphism involving a tandem repeat and the IGF-I
promoter was also associated with an increased risk of development of type 1 diabetes (79).
The CA repeats have also been found in intron-1 in pigs and are associated with lower
serum IGF-I concentrations and increased fat deposition (80). The CA repeat
polymorphisms were also analyzed in a group of young adults. Those with the
polymorphism had a lower serum concentration and had 1 kg lower birth weight and 8 mm
higher systolic blood pressure at age 36 (81). The CA repeat polymorphisms were also
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associated with a lower birth weight and head circumference as well as lower serum IGF-I
levels suggesting that this might predict a later development of cardiovascular disease. IGF-I
gene polymorphisms have also been associated with the development of retinopathy and
nephropathy in patients with established diabetes (82, 83). Polymorphisms in IGFBP-1 have
also been associated with a lower body mass index and the presence of type 2 diabetes (84).
Four single nucleotide polymorphisms were associated with a lower BMI that was
maintained over time and there was a negative relationship between plasma IGFBP-1
concentrations and BMI. Polymorphisms in IGFBP-1 have also been associated with renal
protective effects in type 1 diabetes (85). An IGFBP-3 gene polymorphism has been
described in the promoter region that accounts for an increase in the serum concentrations of
this protein (86). A recent study identified 3 additional polymorphisms and showed that
together the 4 polymorphisms account for 6.5% of the variability of IGFBP-3 in the general
population (87).
Response of patients with genetic syndromes of severe insulin resistance to IGF-I
Several subgroups of patients with severe insulin resistance have been administered IGF-I in
an attempt to achieve improved glycemic control. Patients with severe type A insulin
resistance and mutations in the insulin receptor had major decreases in blood glucose as well
as insulin and C-peptide levels when administered recombinant IGF-I (88). In a subsequent
report, 11 subjects with various types of insulin receptor mutations, were treated up to 16
months with recombinant human IGF-I. Fasting and postprandial glucose as well as
fructosamine and hemoglobin A1C were measured and shown to be significantly improved
in 6 of 11 of the subjects (89). This degree of improvement was maintained throughout
treatment. A subsequent study in patients with severe insulin resistance showed that not only
were glucose and insulin concentrations lowered but insulin resistance as measured using a
frequently sampled intravenous glucose tolerance test showed significant improvement (90).
This was subsequently followed up by another study of 6 subjects, 4 of whom had overt
diabetes and received one month of recombinant IGF-I. Glucose tolerance returned to
normal in 3 of the 4 diabetic subjects and the remaining 2 subjects showed major reduction
in insulin and triglyceride concentrations (91). Two subjects with Rabson-Mendenhall
syndrome showed the same benefits in hemoglobin A1C when IGF-I was administered.
Children with very severe insulin resistance due to leprechanism usually die within the first
two years of life, however, administration of IGF-I to three of these patients has resulted in
several years of maintenance of relatively normal glucose levels and normal linear growth.
Administration of IGF-I to patients with GH receptor mutations who have extremely low
IGF-I concentrations showed that normoglycemia was maintained with suppression of
insulin concentrations (92). Hepatic glucose production was increased presumably due to
enhanced insulin sensitivity and glucose oxidation rates were decreased. IGF-I has been
administered to rare patients with IGF-I gene deletions. In general these subjects have
moderate glucose intolerance or overt diabetes and high fasting GH concentrations (93).
Administration of IGF-I has normalized glucose concentrations and most importantly
normalized insulin sensitivity however since GH is also suppressed it has been impossible to
distinguish between the improving insulin resistance due to suppressing GH as compared to
enhancing insulin sensitivity directly by IGF-I.
IGF-I and the treatment of type 1 diabetes
Multiple studies have administered IGF-I to type 1 diabetics who are also receiving insulin
(94). Many of these studies involved small numbers of subjects although the largest trial had
223 subjects. In that trial the dosages ranged from 20–140 mcg/kg/day. In general
hemoglobin A1C has improved and insulin requirements have decreased. In the large study
with 223 subjects who received IGF-I for 12 weeks there was a major decrease in insulin
requirements and hemoglobin A1C declined by 0.6% (90). Edema, jaw pain, tachycardia
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were present in several subjects (95). Additional subjects (n=4) noted worsening of
retinopathy which resolved during a follow up period after administration of IGF-I had
ceased. IGF-I is also anabolic in these patients and in experimental animals with type 1
diabetes, infusions of IGF-I have been shown to increase long bone growth as well as
protein synthesis (56). Studies using a hyperinsulinemic clamp have shown that
administration of IGF-I is associated with enhanced insulin sensitivity in type 1 diabetes.
Peripheral insulin stimulated glucose disposal increased by approximately 34% during IGF-I
administration (96). Concomitantly with the improvement in insulin resistance was a
lowering of GH. Therefore the question was raised whether most of the improvement was
due to reduced GH secretion. To address this two types of studies were done, Simpson et al
infused octreotide simultaneously with recombinant IGF-I. IGF-I was shown to acutely
reduce hepatic glucose production and stimulate peripheral glucose uptake (97). Glycerol
turnover and free fatty acids were unaffected suggesting to the investigators that the effect
was due to IGF-I enhancement of insulin sensitivity and not a reduction in GH. This was
further addressed using a GH receptor antagonist. A reduction in the GH effect was clearly
achieved with the dosage utilized yet there was no improvement in insulin sensitivity
suggesting to the investigators that the effect of IGF-I is also required (98). When IGF-I was
given insulin sensitivity improved and LDL, triglycerides and the LDL to APO-B ratio were
significantly decreased. In spite of these improvements, significant complications were
noted.
Since administration of relatively high doses IGF-I suppress IGFBP-1 and -2 they result in a
disproportionate increase in free IGF-I. To try to obviate the effects of excessive free IGF-I
in inducing side effects the combination of IGF-I plus IGFBP-3 has also been administered
to type 1 diabetics (99). Pharmacologic studies have shown that when this combination is
given the rate of appearance of free IGF-I is substantially reduced suggesting that it could
lead to fewer side effects (100). Administration of the combination to a group of adult type 1
diabetics resulted in 52% reduction in insulin levels with a 23% reduction in glucose after a
2 week treatment period (99). The prevalence of side effects was reduced. In another study
15 adolescents were administered the combination in doses between 0.1 and 0.8 mg/kg/day.
They showed a 41% reduction in overnight insulin requirements and a dose dependent
reduction in hepatic glucose production (101). Insulin sensitivity was also improved with the
0.4 and 0.8 mg/kg/day dosages. Overnight GH secretion was reduced substantially
suggesting this may be one mechanism by which insulin sensitivity was improved.
Therefore this approach offers a possible future therapeutic option.
IGF-I administration to type 2 diabetics
Several studies with small numbers of patients were initially performed in subjects with type
2 diabetes. Most of these were of short duration (102). Studies that were 7 days or less
showed decreases in glucose, endogenous insulin and C-peptide secretion and in some cases
an improved area under the curve after oral glucose administration. In most of these studies
high doses, (e.g. 240–360 mcg/kg/day) were administered and were associated with edema,
headaches and arthralgias. A longer study wherein IGF-I was administered to 12 subjects for
6 weeks using the dosage of 80 mcg/kg b.i.d. showed a 3.4 fold enhancement in insulin
sensitivity (103). Similarly when 160 mcg/kg/day dose was administered to type 2 diabetics
and hepatic and peripheral insulin sensitivity were measured they were shown to be
improved after 7 days (104). These findings suggested that IGF-I was capable of enhancing
insulin sensitivity in type 2 diabetes. Since most of these subjects are obese and have very
low GH concentrations it is highly likely this is due to an effect on free fatty acid
metabolism in muscle and suppression of renal gluconeogenesis and not simply suppression
of GH secretion.
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A large clinical trial in which doses of 10–80 mcg/kg/day were administered to 212 subjects
for 12 weeks showed that there was a dose dependent reduction in hemoglobin A1C as well
as mean daily blood glucose (105). As in previous trials doses of IGF-I 40 mg/kg bid or
greater were accompanied by a significant side effect profile and the number of side effects
increased as the dosage increased. For example in the 80 mcg/kg bid dose group the number
of subjects having significant side effects was ~30%. This study was followed by a large
trial in which IGF-I was administered to type 2 diabetics who were being given insulin
concomitantly for 12 weeks. Hemoglobin A1C was decreased by an additional 0.8% over
that which could be achieved with more intensive insulinization suggesting that it could be
used as an adjunct to insulin therapy in type 2 diabetes (106). Administration of IGF-I
combined with IGFBP-3 has also been effective in type 2 diabetics. When 48 subjects were
treated with this regimen, fasting and postprandial blood glucose fell significantly by 35–
40% (100). These subjects were being administered insulin and therefore they were able to
be maintained on lower insulin doses. Insulin requirements decreased in the 4 groups by 54–
82% and fasting glucose decreased by 32–37%. The administration of the combination was
associated with fewer side effects but a significant minority of patients had edema,
athralgias and headaches. This suggests that the degree of increase in free IGF-I that has to
be achieved to improve glycemic control is such that even when IGF-I is administered with
its binding protein in order to obtain a clinical improvement in insulin sensitivity the
concentration of free IGF-I that has to be achieved will induce side effects in a substantial
number of patients. These studies suggest that high concentrations of the IGF-I increase
insulin sensitivity in type 2 diabetes but the window between therapeutic utility and toxicity
is relatively small.
Summary
IGF-I is ancestorally related to proinsulin and therefore retains some physiological effects
that complement the ability of insulin to stimulate glucose uptake. Furthermore the actions
of IGF-I are coordinately regulated with GH thus enabling organisms to breakdown fat and
utilize this as a substrate to meet the energy needs that are required for new growth as well
as to coordinate their effects for stimulation of protein synthesis and an anabolic response.
Therefore IGF-I plays an integral role in coordinating the response to nutrient intake and in
initiating the appropriate metabolic changes that enable cells to tolerate a variety of stressful
stimuli and resist apoptosis as well as initiate the tissue repair response that occurs after
injury. Furthermore it plays an important role in facilitating adaption to major changes in
nutrient intake. In this way IGF-I coordinates the response of the three hormones to form a
functional unit thereby coordinating nutrient availability and tissue growth. In obesity and
metabolic syndrome as well as in patients with overt diabetes the metabolic actions of IGF-I
are altered significantly. Similarly its ability to coordinate its functions with those of GH and
insulin is impaired in this pathophysiologic state and this constitutes an important
component of the maladaptive response of all 3 hormones to metabolic stress.
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• IGF-I is an important stimulant of protein synthesis in muscle but it also
stimulates free fatty acid utilization.
• IGF-I actions are regulated by IGF binding proteins and in obesity and
metabolic syndrome there is major dysregulation of IGF binding protein
secretion resulting in alterations in the concentration of free IGF-I and IGF-I
actions.
• In type 1 diabetes, IGF-I synthesis is markedly impaired and in type 2 diabetes
multiple changes occur in IGF-I actions including sensitization to its mitogenic
actions in some target tissues.
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